Atul Bhanudas Shinagare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Atul Bhanudas Shinagare has a total of 421 co-authors. Here are the top co-authors by number of shared publications:
- Jason Laurence Hornick
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
23 shared publications Nikhil H. Ramaiya
Department of Imaging, Dana-Farber Cancer Institute, Boston, USA; Department of Radiology, Brigham and Women's Hospital, Boston, USA
21 shared publicationsJyothi P. Jagannathan
Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA
14 shared publicationsAndrew D. Cherniack
13 shared publicationsJames M. Cleary
13 shared publicationsKimmie Ng
13 shared publications
Latest Publications
- 1 September 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (3)
Diagnostic Accuracy of Bosniak v2019 for Predicting Cancer and Unfavorable Histology in Class III–IV Cystic Renal Masses
This multicenter multinational study demonstrated that Bosniak classification version 2019 can be used to stratify the probability of cancer and cancer with unfavorable histologic features; nodule size was strongly associated with unfavorable histologic features.
- 1 September 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (3)
Diagnostic Accuracy of Bosniak v2019 for Predicting Cancer and Unfavorable Histology in Class III–IV Cystic Renal Masses
This multicenter multinational study demonstrated that Bosniak classification version 2019 can be used to stratify the probability of cancer and cancer with unfavorable histologic features; nodule size was strongly associated with unfavorable histologic features.
- 13 March 2026
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23 (7) , 1253-1260
Certainty Language Use in Pediatric Radiology: A Single-Institution Analysis
- 13 March 2026
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23 (7) , 1253-1260
Certainty Language Use in Pediatric Radiology: A Single-Institution Analysis
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (3) , e250116
Imaging in Advanced Epithelial Ovarian Cancer: Assessment of Peritoneal Spread
Radiologists use CT, along with diffusion-weighted MRI and sometimes PET, to assess disease extent, including peritoneal carcinomatosis, in advanced ovarian cancer, preferably applying systematic image interpretation and disease-specific structured reporting to enhance communication and support decision-making.
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (3) , e250116
Imaging in Advanced Epithelial Ovarian Cancer: Assessment of Peritoneal Spread
Radiologists use CT, along with diffusion-weighted MRI and sometimes PET, to assess disease extent, including peritoneal carcinomatosis, in advanced ovarian cancer, preferably applying systematic image interpretation and disease-specific structured reporting to enhance communication and support decision-making.
- 1 February 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (2) , e243477
Incidental Adnexal Lesions: CT Diagnosis and Interreader Agreement
Even among nine expert readers, CT diagnosis was not reproducible and was frequently incorrect for most adnexal lesion types, excluding dermoids, malignant ovarian lesions with metastases, and simple cysts.
- 1 February 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (2) , e243477
Incidental Adnexal Lesions: CT Diagnosis and Interreader Agreement
Even among nine expert readers, CT diagnosis was not reproducible and was frequently incorrect for most adnexal lesion types, excluding dermoids, malignant ovarian lesions with metastases, and simple cysts.
- 1 January 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (1) , e240223
Gynecologic Manifestations of Hereditary Syndromes: Clinical and Imaging Spectrum
The role of imaging in the diagnosis of gynecologic manifestations of hereditary syndromes is important and allows evaluation of key imaging features and associated conditions.
- 1 January 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (1) , e240223
Gynecologic Manifestations of Hereditary Syndromes: Clinical and Imaging Spectrum
The role of imaging in the diagnosis of gynecologic manifestations of hereditary syndromes is important and allows evaluation of key imaging features and associated conditions.
- 20 November 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (6) , 3115-3124
Follow-up MRI recommendations for adnexal lesions on pelvic ultrasound: frequency, associations and outcomes
Purpose To assess the frequency and outcomes of follow-up MRI recommendations for adnexal lesions on pelvic US interpreted by US experts versus non-US expert abdominal radiologists. Methods In this IRB-approved, HIPAA-compliant retrospective cohort study, all pelvic US reports in adult women between 2018–2023 at a tertiary academic center were screened using a validated NLP algorithm for follow-up MRI recommendations for incidental adnexal lesions. MRI recommendation rates, compliance with the recommendation, and impact of MRI on management (malignancy risk upgrade/no change/downgrade and final outcomes) were compared between US expert and non-US expert abdominal radiologists. Results Of 19,335 pelvic US in 14,328 patients (15,609, 80.7% read by US experts, 3726, 19.3% by non-US expert abdominal radiologists), 458 (2.3%) had follow-up MRI recommendations. US experts made fewer recommendations (248, 1.5% vs 210, 5.6%; p < 0.001) and had higher compliance rate (157, 63.3% vs 108, 51.4%; p = 0.01). MRI caused risk downgrade, no change, and upgrade in 191 (72.1%), 62 (23.4%), and 12 (4.5%) respectively; without significant difference between US experts and non-US experts (113, 72%, 39, 24.8%, 5, 3.2% vs 78, 72.2%, 23, 21.3%, 7, 6.5%; p = 0.96). Of 191 lesions with risk-downgrade, 124 underwent surgery (n = 60) or follow-up (n = 64) without any cancers; 67 had no further follow-up. Of 12 lesions with risk-upgrade on MRI, 6 (50%) were malignant, 4 (33.3%) benign, 2 (16.7%) borderline. Of 193 cases where MRI was not performed, 60 were resected (53, 88.3% benign, 3, 5.0% borderline, 4, 6.7% malignant). Conclusion US experts made fewer follow-up MRI recommendations, with no difference in the impact of MRI on risk-assessment between US experts and non-US expert radiologists. MRI resulted in malignancy risk-downgrade in most lesions and can potentially avoid unnecessary surgeries.
- 20 November 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (6) , 3115-3124
Follow-up MRI recommendations for adnexal lesions on pelvic ultrasound: frequency, associations and outcomes
Purpose To assess the frequency and outcomes of follow-up MRI recommendations for adnexal lesions on pelvic US interpreted by US experts versus non-US expert abdominal radiologists. Methods In this IRB-approved, HIPAA-compliant retrospective cohort study, all pelvic US reports in adult women between 2018–2023 at a tertiary academic center were screened using a validated NLP algorithm for follow-up MRI recommendations for incidental adnexal lesions. MRI recommendation rates, compliance with the recommendation, and impact of MRI on management (malignancy risk upgrade/no change/downgrade and final outcomes) were compared between US expert and non-US expert abdominal radiologists. Results Of 19,335 pelvic US in 14,328 patients (15,609, 80.7% read by US experts, 3726, 19.3% by non-US expert abdominal radiologists), 458 (2.3%) had follow-up MRI recommendations. US experts made fewer recommendations (248, 1.5% vs 210, 5.6%; p < 0.001) and had higher compliance rate (157, 63.3% vs 108, 51.4%; p = 0.01). MRI caused risk downgrade, no change, and upgrade in 191 (72.1%), 62 (23.4%), and 12 (4.5%) respectively; without significant difference between US experts and non-US experts (113, 72%, 39, 24.8%, 5, 3.2% vs 78, 72.2%, 23, 21.3%, 7, 6.5%; p = 0.96). Of 191 lesions with risk-downgrade, 124 underwent surgery (n = 60) or follow-up (n = 64) without any cancers; 67 had no further follow-up. Of 12 lesions with risk-upgrade on MRI, 6 (50%) were malignant, 4 (33.3%) benign, 2 (16.7%) borderline. Of 193 cases where MRI was not performed, 60 were resected (53, 88.3% benign, 3, 5.0% borderline, 4, 6.7% malignant). Conclusion US experts made fewer follow-up MRI recommendations, with no difference in the impact of MRI on risk-assessment between US experts and non-US expert radiologists. MRI resulted in malignancy risk-downgrade in most lesions and can potentially avoid unnecessary surgeries.
- 5 August 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (11) , 1390-1398
Potential Frameworks for Communicating Diagnostic Certainty in Radiology Reports: From the ACR Commission on Quality and Safety
- 5 August 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (11) , 1390-1398
Potential Frameworks for Communicating Diagnostic Certainty in Radiology Reports: From the ACR Commission on Quality and Safety
- 19 March 2025
- Published by Springer Nature in European Radiology
- Vol. 35 (9) , 5220-5222
Next-Gen Radiology: Disease-specific structured reports
- 19 March 2025
- Published by Springer Nature in European Radiology
- Vol. 35 (9) , 5220-5222
Next-Gen Radiology: Disease-specific structured reports
- 30 May 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 21 (6) , S249-S267
ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Invasive Cancer of the Cervix: 2023 Update
- 30 May 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 21 (6) , S249-S267
ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Invasive Cancer of the Cervix: 2023 Update